<DOC>
	<DOC>NCT02047500</DOC>
	<brief_summary>This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.</brief_summary>
	<brief_title>Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects greater than or equal to (&gt;=) 18 years of age with locally advanced unresectable or metastatic pancreatic adenocarcinoma proven by histology or cytology and previously untreated with chemotherapy or systemic therapy other than: Radiosensitizing doses of 5fluorouracil; Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months after completion of gemcitabine; Neoadjuvant chemotherapy if relapse occurred at least 6 months after surgical resection; Adjuvant chemotherapy if relapse occurred at least 6 months after completion of adjuvant chemotherapy Subjects may have measurable or nonmeasurable disease according to RECIST 1.1. Eastern cooperative oncology group (ECOG) performance status of 0 or 1 Acceptable hematological status, liver and renal function as defined in the protocol Other protocol defined inclusion criteria could apply Significant cardiac or peripheral vascular arterial disease Known brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 3 months) Severe chronic obstructive or other pulmonary disease with hypoxemia Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy Subjects receiving concomitant treatment with radiotherapy or other investigational drugs Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>TH-302</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Evofosfamide</keyword>
</DOC>